Search

Displaying results 321 - 330 of 4265 in total
  1. Drug

    Fusidic acid

    go.drugbank.com/drugs/DB02703
    ApprovedInvestigational

    It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections. … (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.

  2. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.

  3. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.

  4. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates

  5. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    When provided as Concerta®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is … [F4474] When provided as Biphentin®, methylphenidate is released through a multi-layer release delivery system (MLRTM) where 40% of the dose is provided as an immediate release and 60% is provided through

  6. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections.

  7. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. … It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.

  8. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.

  9. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. … [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.

  10. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.